Stock Track | Kiniksa Pharmaceuticals Plunges 5.04% in Pre-market on Q4 Earnings Miss

Stock Track02-24

Kiniksa Pharmaceuticals Ltd. (KNSA) experienced a pre-market plunge of 5.04% on Tuesday, following the release of its fourth-quarter financial results.

The sharp decline appears to be driven by the company's earnings per share (EPS) falling short of analyst expectations. Kiniksa reported Q4 EPS of $0.17, which missed the consensus estimate of $0.38 by a significant 54.67%. Another source noted the result was $0.17 versus a FactSet estimate of $0.34. While quarterly sales of $202.127 million surpassed estimates, the substantial earnings miss weighed heavily on investor sentiment.

Concurrently, the company provided its 2026 net product revenue guidance for Arcalyst, projecting between $900 million and $920 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1101216014?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101216014","market":"hk","top_or_hot":-1,"title":"Stock Track | Kiniksa Pharmaceuticals Plunges 5.04% in Pre-market on Q4 Earnings Miss","media":"Stock Track","content":"<p>Kiniksa Pharmaceuticals Ltd. (KNSA) experienced a pre-market plunge of 5.04% on Tuesday, following the release of its fourth-quarter financial results.</p><p>The sharp decline appears to be driven by the company's earnings per share (EPS) falling short of analyst expectations. Kiniksa reported Q4 EPS of $0.17, which missed the consensus estimate of $0.38 by a significant 54.67%. Another source noted the result was $0.17 versus a FactSet estimate of $0.34. While quarterly sales of $202.127 million surpassed estimates, the substantial earnings miss weighed heavily on investor sentiment.</p><p>Concurrently, the company provided its 2026 net product revenue guidance for Arcalyst, projecting between $900 million and $920 million.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Kiniksa Pharmaceuticals Plunges 5.04% in Pre-market on Q4 Earnings Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Kiniksa Pharmaceuticals Plunges 5.04% in Pre-market on Q4 Earnings Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-24 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Kiniksa Pharmaceuticals Ltd. (KNSA) experienced a pre-market plunge of 5.04% on Tuesday, following the release of its fourth-quarter financial results.</p><p>The sharp decline appears to be driven by the company's earnings per share (EPS) falling short of analyst expectations. Kiniksa reported Q4 EPS of $0.17, which missed the consensus estimate of $0.38 by a significant 54.67%. Another source noted the result was $0.17 versus a FactSet estimate of $0.34. While quarterly sales of $202.127 million surpassed estimates, the substantial earnings miss weighed heavily on investor sentiment.</p><p>Concurrently, the company provided its 2026 net product revenue guidance for Arcalyst, projecting between $900 million and $920 million.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KNSA","symbol_name":"Kiniksa Pharmaceuticals Ltd.","start_time":0,"source_url":"","article_id":"1101216014","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101216014","pubTimestamp":1771938166,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Kiniksa Pharmaceuticals Ltd. (KNSA) experienced a pre-market plunge of 5.04% on Tuesday, following the release of its fourth-quarter financial results.The sharp decline appears to be driven by the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KNSA":"Kiniksa Pharmaceuticals Ltd."},"translate_title":"个股追踪|Kiniksa Pharmaceuticals盘前暴跌5.04%财报未达预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KNSA":1},"content_text":"Kiniksa Pharmaceuticals Ltd. (KNSA) experienced a pre-market plunge of 5.04% on Tuesday, following the release of its fourth-quarter financial results.The sharp decline appears to be driven by the company's earnings per share (EPS) falling short of analyst expectations. Kiniksa reported Q4 EPS of $0.17, which missed the consensus estimate of $0.38 by a significant 54.67%. Another source noted the result was $0.17 versus a FactSet estimate of $0.34. While quarterly sales of $202.127 million surpassed estimates, the substantial earnings miss weighed heavily on investor sentiment.Concurrently, the company provided its 2026 net product revenue guidance for Arcalyst, projecting between $900 million and $920 million.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1101216014","isCrawlerRequest":true}